A Phase I, Open Label, Parallel Group, Pharmacokinetic Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function

Trial Profile

A Phase I, Open Label, Parallel Group, Pharmacokinetic Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Dec 2016

At a glance

  • Drugs Trastuzumab emtansine (Primary)
  • Indications Advanced breast cancer; Male breast cancer
  • Focus Pharmacokinetics
  • Sponsors Roche
  • Most Recent Events

    • 12 Mar 2016 Results (n=28) presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
    • 26 Jan 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 20 Oct 2014 Planned End Date changed from 1 Oct 2014 to 1 Dec 2014 according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top